CAJ | 학술논문

酪氨酸激酶抑制剂(TKI)厄洛替尼作为晚期非小细胞肺癌(NSCLC)靶向治疗药物,延长了患者的生存时间,但其耐药性的发生成为其进一步应用的瓶颈.现已证实T790M突变、KRAS突变、c-met癌基因扩增在耐药机制中起重要作用.针对不同耐药机制,第2代TKI的应用、再次应用化疗或厄洛替尼以及针对失败模式进行后续治疗等多项临床试验不断开展.
락안산격매억제제(TKI)액락체니작위만기비소세포폐암(NSCLC)파향치료약물,연장료환자적생존시간,단기내약성적발생성위기진일보응용적병경.현이증실T790M돌변、KRAS돌변、c-met암기인확증재내약궤제중기중요작용.침대불동내약궤제,제2대TKI적응용、재차응용화료혹액락체니이급침대실패모식진행후속치료등다항림상시험불단개전.
Erlotinib,a kind of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs),has been effectively used in the treatment of non-small cell lung cancer (NSCLC).Although it prolongs patients survival time,erlotinib is limited to be further applied for its resistance.It has been proved that threonine to methionine mutations in codon 790 (T790M),Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation and the amplification of met oncogene play important roles in the drug resistance.Based on the different molecular mechanisms of resistance,multiple clinical trials of the second generation TKIs,retreatment of chemotherapy or erlotinib and subsequent treatment according to failure modes have been developed.